1344. Tedizolid for Treatment of Enterococcal Bacteremia
Session: Poster Abstract Session: Clinical Trials
Friday, October 28, 2016
Room: Poster Hall
Posters
  • Tedizolid IDWEEK 2016 - 1344p.pdf (496.8 kB)
  • Background: Due to the high prevalence of vancomycin-resistant enterococci (VRE) and emergence of daptomycin-nonsusceptible enterococci (DNSE) in the US hospital settings, tedizolid provides an alternative choice for the treatment of serious infections caused by VRE and DNSE. We share our experience in treatment of enterococcal bacteremia with a focus on DNSE using tedizolid as salvage antibiotic therapy.

    Methods: DNSE and VRE isolates were identified on the basis of colony morphology, conventional biochemical tests, and were confirmed by analysis of 16S rRNA gene sequence or by the MALDI Biobiotyper CA System (Bruker). DNSE was defined as an enterococci isolate with a daptomycin minimum inhibitory concentration (MIC) of >4 μg/ml as determined by MicroScan System (Siemens)) and confirmed by Etest (bioMérieux). In vitro susceptibility of tedizolid and linezolid for these isolates were performed by broth microdilution using the Sensititre™ panel (Thermo Fisher Scientific) in accordance with the guidelines of the Clinical and Laboratory Standards Institute (CLSI).

    Results: 4 patients with E. faecium bacteremia were treated with tedizolid 200 mg once a day in a medical center in suburban New York City from November 2014 through June 2015. Tedizolid was used as salvage therapy in these patients who had multiple contraindications for treatment with other antibiotics based on susceptibility data, existing laboratory abnormalities and potential drug interactions.

    Case

    Patient Characteristics

    Indication of treatment

    DAP

    MIC

    μg/ml

    LIN

    MIC μg/ml

    TED

    MIC μg/ml

    Duration of Treatment (Days)

    Outcome

    1

    60/M renal transplantation

    VRE bacteremia

    Rhabdomyolysis, thrombocytopenia

    4

    1

    0.25

    14

    Cure

    2

    75/M Burkitt’s lymphoma

    DNSE bacteremia

    16

    2

    0.25

    14

    Cure

    3

    49/M Cirrhosis

    DNSE bacteremia

    6

    2

    0.25

    10

    Cure

    4

    54/F Acute Leukemia

    DNSE bacteremia

    32

    2

    0.25

    7

    Cure

    Conclusion: Our clinical data confirms the microbiological and pharmacological basis for potential use of tedizolid as salvage therapy in patients with infections caused by daptomycin-nonsusceptible enterococci.

    Praveen Sudhindra, MD, Westchester Medical Center, valhalla, NY, Leslie Lee, PharmD, Westchester Medical Center, Valhalla, NY, Guiqing Wang, MD, PhD, Pathology and Clinical Laboratories, New York Medical College/ Westchester Medical Center, Valhalla, NY and Abhay Dhand, MD, Transplant Infectious Diseases, Westchester Medical Center, Valhalla, NY

    Disclosures:

    P. Sudhindra, None

    L. Lee, None

    G. Wang, None

    A. Dhand, Merck: Speaker's Bureau , Speaker honorarium

    See more of: Clinical Trials
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.